pediatric cancer

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Immatics N.V.

Immatics' Experimental Cancer Therapy Achieves Remission in Teen with Advanced Tumor

Immatics' PRAME-directed TCR therapy achieves deep remission in advanced pediatric cancer patient, validating engineered T-cell approach in solid tumors.
MRNAIMTXpediatric cancercell therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Day One Biopharmaceuticals Posts 172% Revenue Growth on OJEMDA Sales Strength

Day One Biopharmaceuticals reports 172% revenue growth to $155.4M, driven by OJEMDA sales strength. Company acquires Mersana Therapeutics to expand pipeline.
DAWNclinical trialsrevenue growth